2023. Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Body Surface Area (BSA) Involvement and Baseline Psoriasis Area and Severity Index (PASI). SKIN The Journal of Cutaneous Medicine. 7, 6 (Nov. 2023), s238. DOI:https://doi.org/10.25251/skin.7.supp.238.